Suppr超能文献

重症监护中存在瑞芬太尼急性耐受的证据,但麻醉中不存在。

Evidence of acute tolerance to remifentanil in intensive care but not in anesthesia.

作者信息

Fodale Vincenzo, Pratico Caterina, Tescione Marco, Tanania Salvatore, Lucanto Tullio, Santamaria Letterio B

机构信息

Department of Neuroscience, Psychiatric and Anesthesiological Sciences, University of Messina, School of Medicine, Policlinico Universitario "G.Martino", 98125 Messina, Italy.

出版信息

J Clin Anesth. 2006 Jun;18(4):293-6. doi: 10.1016/j.jclinane.2005.08.015.

Abstract

We report the case of a 19-year-old man with a drug abuse history, admitted to the intensive care unit for head and chest trauma, who experienced an acute tolerance to sedative and respiratory depression effects of remifentanil, which was given as the sole agent for sedation. He did not exhibit any signs of drug tolerance or intraoperative awareness during prolonged remifentanil-based anesthesia using propofol or sevoflurane as adjuvants. Several recent studies support the hypothesis of a possible involvement of N-methyl-d-aspartate glutamate receptors. The clinical relevance of this report is that if a patient with a previously acute tolerance to remifentanil during sedation undergoes long-term surgery, and propofol or sevoflurane is coadministered in a remifentanil-based anesthesia, the patient will not necessarily develop opioid tolerance. It is of interest for anesthesiologists, given the high frequency of patients with drug abuse history who are admitted to intensive care units, often sedated with remifentanil, who undergo anesthesia for emergency surgery.

摘要

我们报告了一名有药物滥用史的19岁男性病例,该患者因头部和胸部创伤入住重症监护病房,对作为唯一镇静剂使用的瑞芬太尼的镇静和呼吸抑制作用产生了急性耐受性。在以瑞芬太尼为主、丙泊酚或七氟醚作为辅助剂的长时间麻醉过程中,他未表现出任何药物耐受性或术中知晓的迹象。最近的几项研究支持N-甲基-D-天冬氨酸谷氨酸受体可能参与其中的假说。本报告的临床意义在于,如果一名在镇静期间对瑞芬太尼曾有过急性耐受性的患者接受长期手术,并且在以瑞芬太尼为主的麻醉中联合使用丙泊酚或七氟醚,该患者不一定会产生阿片类药物耐受性。鉴于入住重症监护病房、常使用瑞芬太尼镇静且接受急诊手术麻醉的有药物滥用史患者的高频率,这对麻醉医生来说是值得关注的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验